High-Density Genomewide Linkage Analysis of Exceptional Human Longevity Identifies Multiple Novel Loci by Boyden, Steven E. & Kunkel, Louis M.
High-Density Genomewide Linkage Analysis of
Exceptional Human Longevity Identifies Multiple Novel
Loci
Steven E. Boyden
1,2, Louis M. Kunkel
1,2,3*
1Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America, 2Program in Genomics, Division of Genetics, and The Manton Center
for Orphan Disease Research, Children’s Hospital Boston, Boston, Massachusetts, United States of America, 3Howard Hughes Medical Institute, Children’s Hospital Boston,
Boston, Massachusetts, United States of America
Abstract
Background: Human lifespan is approximately 25% heritable, and genetic factors may be particularly important for
achieving exceptional longevity. Accordingly, siblings of centenarians have a dramatically higher probability of reaching
extreme old age than the general population.
Methodology/Principal Findings: To map the loci conferring a survival advantage, we performed the second genomewide
linkage scan on human longevity and the first using a high-density marker panel of single nucleotide polymorphisms. By
systematically testing a range of minimum age cutoffs in 279 families with multiple long-lived siblings, we identified a locus
on chromosome 3p24-22 with a genomewide significant allele-sharing LOD score of 4.02 (empirical P=0.037) and a locus
on chromosome 9q31-34 with a highly suggestive LOD score of 3.89 (empirical P=0.054). The empirical P value for the
combined result was 0.002. A third novel locus with a LOD score of 4.05 on chromosome 12q24 was detected in a subset of
the data, and we also obtained modest evidence for a previously reported interval on chromosome 4q22-25.
Conclusions/Significance: Our linkage data should facilitate the discovery of both common and rare variants that
determine genetic variability in lifespan.
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Introduction
Many common diseases of adulthood increase in prevalence
with age. These morbidities accompany an exponential increase in
mortality rate that is maintained until approximately age 90,
whereupon it starts to decelerate [1]. The reduction in observed
versus expected mortality may be due to demographic selection,
whereby individuals with alleles predisposing them to an early or
average age of death, once deceased, leave behind a robust cohort
depleted of detrimental alleles and/or enriched for alleles that
promote longevity [2,3]. Centenarians often reach old age with
delayed onset or absence of geriatric diseases [4], possibly
benefitting from a ‘‘compression of morbidity’’ that confines these
diseases to a short duration at the end of their life [5]. This
correlation between exceptional longevity and healthy aging
suggests that common genetic factors may underlie both traits.
The epidemiology and phenotypes characteristic of human aging
and results of candidate gene association studies have been
reviewed elsewhere [6–8]. While many variants have demonstrat-
ed preliminary evidence of association to exceptional longevity [7],
the only confirmed associations are those of the APOE (MIM
107741) haplotypes [9–12]. Multiple recently reported associations
between variants in FOXO3 (MIM 602681) and longevity are also
quite promising [13–18]. Despite these important discoveries,
additional alleles that may regulate aging in humans and allow a
minority of the population to attain extreme old age have likely yet
to be identified.
Estimates of the heritability of normal human lifespan range
from 10% to 58%, averaging about 25% [19]. The genetic
contribution to lifespan grows markedly after age 60, indicating
the heritability of exceptional longevity may be substantially
higher than these estimates [20]. The relative survival probability
for siblings of centenarians increases steadily with age, until male
and female siblings have a 17-fold and 8-fold increased chance,
respectively, of reaching age 100 compared to others from their
birth cohort [21]. Moreover, while natural lifespan is likely a
complex trait controlled by many genes with small effect sizes,
extreme longevity may be determined by fewer genes of stronger
effect [22,23], and may therefore be amenable to linkage analysis.
The only previous genomewide scan for linkage to longevity was
conducted in part by a member of our group (LMK) and identified
a region on chromosome 4q22-25 as significantly linked in 137
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genomewide scan for healthy aging in a smaller and younger
cohort provided weak support for the chromosome 4q22-25
linkage [25], whereas a targeted study of 164 sibships of
nonagenarians did not find linkage to the locus [26], nor did a
genomewide scan on bone characteristics as a biomarker for
biological aging [27]. All these studies used microsatellite markers
with 5–10 cM spacing. To assess the linkage to chromosome 4 and
identify new loci, we performed the most powerful linkage scan to
date on exceptional longevity. Though the evidence for linkage to
chromosome 4 remains equivocal, several novel loci were
discovered in our scan, including a region on chromosome
3p24-22 with an empirically genomewide significant LOD score of
4.02 and a region on chromosome 9q31-34 with a LOD score of
3.89.
Methods
Ethics Statement
Subjects were recruited through Elixir Pharmaceuticals, the
New England Centenarian Study (NECS) now of Boston
University Medical Center, Beth Israel Deaconess Medical Center
(BIDMC), and Children’s Hospital Boston (CHB), as described
previously [24,28]. All participants provided written informed
consent and the study was approved by the Institutional Review
Boards of the above institutions. All samples were de-identified
and were either available from BIDMC or CHB, or were
purchased from Elixir Pharmaceuticals or NECS for a processing
fee.
Subjects
All subjects provided proof of age. There was a predominance
of female subjects in our cohort, likely reflecting the original
ascertainment criterion of having a proband of at least 98 years of
age regardless of gender [24]. Only self-identified white or
Caucasian subjects (the vast majority of our cohort) were analyzed,
since population stratification can confound nonparametric
linkage analysis when parental genotypes are unobserved [29].
We had available gender, age at last contact, and alive versus
deceased status as of last contact. Age at last contact was not a
suitable approximation for our phenotype of interest, age at death,
because 70% of our cohort was living. To produce a more
homogeneous phenotype that would better estimate age at death,
we calculated an expected age at death, which for deceased
subjects was equal to their actual age at death, and for living
subjects was equal to their age at last contact plus their age-specific
and gender-specific life expectancies from life tables for the 1900
birth cohort [30]. The median year of birth for our cohort was
1901.
Since we could not predict what minimum age requirements
would provide optimal power, ten sets of gender-specific minimum
expected age at death requirements were applied to all subjects,
with the hypothesis that as the cutoffs increased, the loss of power
due to the decreasing number of families might be partially offset
by an increase in genetic homogeneity and/or magnitude of effects
in older subjects. As designated hereafter, Categories 1 to 10 cover
the range from the upper 5% to the upper 0.2% tail of the birth
cohort, corresponding to a minimum expected age at death of 90
to 100 for males and 95 to 104 for females (Table 1). Subjects that
did not meet the age criteria for a category were removed from the
analysis; for sibships with more than two siblings, individual
siblings were excluded while retaining the sibship, whereas once
either member of a sibling pair was eliminated, the entire sibship
was removed.
In addition to analyzing the complete Categories 1 to 10 (the
‘‘Total’’ group), we divided the sample set by two criteria into two
subgroups for each. To explore differences between this study and
the first scan [24], we analyzed (in Category 1) 129 of the 137
families used in the original cohort (the ‘‘Previous’’ subgroup)
separately from 150 families recruited since that study was
completed (the ‘‘New’’ subgroup). Because life expectancies show
a gender bias, we also split the Total group into 140 sibships (in
Category 1) with at least one male member (the male-containing,
or ‘‘MC’’ subgroup) and 139 sibships comprised of only females
(the female-only, or ‘‘FO’’ subgroup) (Table S1). Results that apply
across all ten categories, in any group, are referred to as ‘‘Overall’’
for that group (for example, the Overall maximum LOD score).
Genotyping and Filtering
Genomic DNA samples were purified from blood as described
previously [24], and were subjected to whole genome amplifica-
tion using the GenomiPhi kit (Amersham). Amplified DNA was
genotyped at 10,204 single nucleotide polymorphisms (SNPs) on
the GeneChip Human Mapping 10K 2.0 Array (Affymetrix).
Samples that did not achieve at least a 95% SNP Call Rate were
re-genotyped or excluded. Genotype concordance checks were
performed to verify sibling status and eliminate duplicate samples,
monozygotic twins, and unrelated subjects. Seven sibships were
found to be comprised of at least one pair of half-siblings, which
were included. Among 642 successfully genotyped samples, of
which 632 subjects in 279 sibships qualified for Category 1, the
mean SNP Call Rate was 98.81%, ranging from 95.03% to
99.87%. There were 109 SNPs that were not assigned to a
chromosome, 170 SNPs that had a Hardy-Weinberg equilibrium
P value below 10
23 among 282 unrelated subjects, and 267 SNPs
that had a call rate of below 90% across all 642 samples. A total of
453 SNPs meeting one or more of these criteria was eliminated,
resulting in a final panel of 9751 SNPs.
Linkage Analysis
Linkage analysis was performed using MERLIN/MINX v1.1.2
[31]. Genotype data were converted into MERLIN-compatible
input files using the Affymetrix tool GDASPort. All siblings were
encoded as affected and their ungenotyped parents were encoded
as phenotype unknown. Marker map positions based on the
deCODE Genetics sex-averaged genetic map and marker allele
frequencies for a Caucasian population were provided by
Affymetrix. The Total group was also analyzed allowing MERLIN
to calculate founder marker allele frequencies in each category
separately, and the results were negligibly different than with the
Affymetrix frequencies (data not shown).
We computed a multipoint nonparametric Kong and Cox
allele-sharing LOD score with the Sall scoring function and the
exponential allele-sharing model [32], since the commonly used
nonparametric linkage (NPL) score is overly conservative with
missing data [32–34] and our parental genotypes were universally
absent. Hereafter, ‘‘LOD score’’ refers to these conditions. A
parametric heterogeneity LOD (hLOD) score was also computed
under both a dominant and recessive model, along with a
conventional parametric LOD score. The penetrance for non-
susceptible genotypes (phenocopy) under each model was
arbitrarily set to one-tenth the birth cohort trait prevalence for
that age category, and the penetrance for the susceptible genotypes
was set to 1 since we analyzed only affected subjects. The
‘‘disease’’ allele frequencies were then calculated to fit the
prevalence and penetrance model (Table S1). To limit the
multiple testing burden, the results were screened only on the
basis of the nonparametric LOD scores; parametric hLOD and
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nonparametric LOD scores were considered interesting (LOD$2).
The hLOD scores were used to verify that the nonparametric
results were robust to different assumptions and provide
information about the possible mode of inheritance of the putative
longevity allele. Empirical P values were determined solely on the
basis of nonparametric LOD scores.
We used the --rsq option in MERLIN [35] to accommodate
linkage disequilibrium (LD) between markers. SNPs for which the
pairwise coefficients of determination (r
2) exceeded 0.16, above
which LOD score inflation due to inter-marker LD becomes
appreciable when parental genotypes are unobserved [36], were
clustered with intervening SNPs and treated as a single multi-
allelic marker. The error checking and Pedwipe functions of
MERLIN were used to remove unlikely genotypes as implied by
close double crossovers. Mendelian inheritance errors could not be
identified due to the lack of parental genotypes.
Empirical P Values
To account for the multiple partially-dependent hypotheses
represented by the ten age categories, we calculated an Overall
empirical P value for linkage peaks from any category in the Total
group that met the significance threshold of LOD =3.6 for a single
genomewide scan with a fully informative marker panel [37]. Based
on the error-wiped pedigrees from Category 1, MERLIN was used to
generate 1000 replicates of simulated genotype data under the null
hypothesis of no linkage, applying the same marker map, allele
frequencies, LD-corrected cluster definitions and haplotype frequen-
cies (generated from the original scan with the --cfreq option), and
missing data pattern as the actual data. The replicate pedigree files
were successively trimmed nine times each to produce the
corresponding pedigree files for Categories 2 to 10. These 1000 sets
of ten replicates were analyzed identically to the actual data, and the
number of distinct replicates or genomic locations in like replicates
across all age categories that met or exceeded the observed LOD
score for a given peak was recorded. If a replicate exceeded the
observed LOD score in multiple categories at the same location, it
was counted only once, just as in the original analysis.
We used the formula P=(r+1)/(n+1) to calculate empirical P values,
where r is the number of replicates reaching the observed LOD score,
and n is the number of replicates analyzed [38]. This formula produces
a biased estimate of the true underlying P value, but provides a more
accurate estimate of the type I error rate than the conventional,
unbiased (yet anticonservative) formula P=r/n [38–41]. Upper 95%
confidence limits for empirical P values were calculated using the
conservative Clopper-Pearson exact method for a binomial distribution
[42], as implemented in an online calculator [43].
Results
In the Total group we identified a region on chromosome 3p24-
22 with an Overall maximum LOD score of 4.02 in Category 4,
Table 1. Subject characteristics by age category for Total group.
Age Category 1 2 3 4 5 6 7 8 9 10
Upper tail of 1900 birth cohort 5% 4% 3% 2.5% 2% 1.5% 1% 0.5% 0.3% 0.2%
Minimum expected age
at death (male)
90 91 92 93 94 95 96 98 99 100
Minimum expected age
at death (female)
95 96 97 98 99 100 101 102 103 104
Sibships 279 273 261 243 212 191 155 95 66 34
2-ships 218 217 209 209 185 172 140 86 61 32
3-ships 50 46 43 27 23 15 13 9 5 2
4-ships 9 875442000
5-ships 2 222000000
% .2-ships 21.9 20.5 19.9 14.0 12.7 9.9 9.7 9.5 7.6 5.9
Average sibship size 2.27 2.25 2.24 2.18 2.15 2.12 2.11 2.09 2.08 2.06
Subjects 632 614 585 529 455 405 327 199 137 70
Average age at last contact 99.4 99.5 99.7 100.0 100.4 100.6 101.0 101.8 102.2 103.1
Subjects deceased at last contact 192 186 174 161 136 114 92 60 33 15
Subjects alive at last contact 440 428 411 368 319 291 235 139 104 55
Average life expectancy of
subjects alive
2.4 2.4 2.4 2.3 2.2 2.2 2.1 2.0 2.0 1.8
Average expected age at death 101.1 101.2 101.4 101.6 102.0 102.2 102.5 103.2 103.7 104.5
Average expected age at death
(male)
99.3 99.4 99.5 99.5 99.9 99.9 100.2 101.2 101.6 102.6
Average expected age at death
(female)
101.8 101.9 102.2 102.6 103.1 103.4 103.9 104.6 105.0 106.0
Male subjects 177 174 172 171 155 144 123 79 54 30
Female subjects 455 440 413 358 300 261 204 120 83 40
% Male subjects 28.0 28.3 29.4 32.3 34.1 35.6 37.6 39.7 39.4 42.9
Age, gender, and sibship composition statistics for the Total group are given across ten categories defined by gender-specific minimum requirements for expected age
at death. The designations 2-ship, 3-ship, 4-ship, and 5-ship refer to sibships with two, three, four, or five siblings, respectively.
doi:10.1371/journal.pone.0012432.t001
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LOD score of 3.89 in Category 8. No other intervals achieved a
LOD score above 3.0 (Figure 1), and given the high probability
that peaks below that magnitude represent false positives, they
were not considered further. By averaging the simulation results
across all ten age categories, we calculated the per-category
empirical threshold for genomewide significance with a type I
error rate of a=0.05 to be a LOD score of approximately 3.1,
likely reflecting the imperfect informativity of the 10K panel [37].
Correcting for all categories, a LOD score of approximately 3.9
was required for Overall genomewide significance. For the
chromosomes 3 and 9 linkage peaks, respectively, we observed
36 and 53 distinct genomic locations among 1000 sets of replicates
for which a LOD score in any age category met or exceeded the
observed scores, resulting in corresponding empirical P values of
0.037 [upper 95% confidence limit 0.048] and 0.054 [upper 95%
confidence limit 0.067]. Only a single replicate achieved two LOD
scores of at least 3.89 at distinct locations across all categories,
yielding an empirical P value for the combined result of 0.002
[upper 95% confidence limit 0.006]. The stability of the
chromosomes 3 and 9 linkage peaks was evaluated by dividing
the marker panel into two independent subsets containing every
other SNP, and both regions retained strong evidence for linkage
in the halved panels (data not shown).
The LOD scores for all linkage peaks varied considerably by
group (Figure 2). The chromosome 4q22-25 linkage peak reported
previously [24] produced an Overall maximum LOD score of 1.01
in Total Category 2. In the same region in the Previous subgroup
we obtained maximum LOD scores of 2.14, 1.99, and 2.20 in
Categories 1 to 3, respectively, whereas in the New subgroup,
there was no evidence for linkage. For chromosomes 3 and 9, the
Previous subgroup provided strong evidence for linkage with LOD
scores of 3.90 in Category 4 (Overall maximum 4.49 in Category
5) and 3.43 in Category 8, respectively, while in the New subgroup
the corresponding maximum LOD scores were 1.19 and 1.12.
Analysis of the New subgroup also revealed a third novel locus on
chromosome 12q24 with an Overall maximum LOD score of 4.05
in Category 6. This peak was completely absent from the Previous
subgroup, and accordingly, the original cohort [24]. The Overall
maximum LOD score for the chromosome 12 peak in the Total
group was 1.11 in Category 5.
We did not discover any additional linkage peaks in the gender-
stratified analyses. The chromosome 3 linkage peak was somewhat
stronger in the FO group (Overall maximum LOD score of 2.77 in
Category 5) than in the MC group (Overall maximum LOD score
of 1.85 in Category 4), whereas the chromosome 9 linkage peak
showed a greater difference in the opposite direction (Overall
maximum LOD scores of 3.62 in MC Category 8 and 1.30 in FO
Category 9, though the disparity may be explained by the greater
number of MC than FO sibships in Categories 8 and 9). The
subgroup characteristics are given in Table S1, and the complete
nonparametric linkage data for the Total group and all four
subgroups are provided in Text S1, S2, S3, S4 and S5.
The parametric analysis generally supported the results of the
nonparametric analysis, showing all four linkage peaks in their
respective groups and categories to be robust to different
assumptions about the mode of inheritance. The chromosome 3
peak produced a higher maximum hLOD score under a recessive
model (4.652) than a dominant model (3.334), whereas the
maximum hLOD score for the chromosome 9 peak was higher
under the dominant model (3.883) than the recessive model
(2.680). The dominant model on chromosome 9 also yielded
positive conventional parametric LOD scores of 1.047 in Category
8 and 2.840 in Category 9, suggesting reduced locus heterogeneity
in the oldest sibships. The chromosome 12 peak achieved similar
maximum hLOD scores of 3.915 and 3.875 under the dominant
and recessive models, respectively, which likewise produced similar
results on chromosome 4. We did not assess whether differences in
hLOD scores under the dominant and recessive models were
significant. Overall maximum nonparametric LOD and paramet-
ric hLOD scores, P values, and linkage peak locations for
chromosomes 3, 9, 12, and 4 are given in Table 2.
Discussion
We performed the second genomewide linkage scan on families
of exceptionally long-lived siblings, with substantial improvements
in power over the first scan [24]. A filtered panel of 9751 SNPs
with an average minor allele frequency of 0.27, equivalent to
approximately 4000 microsatellite markers [44], provided a ten-
fold effective increase in marker density over the original scan. The
resulting advantage in information content and power of similar
SNP arrays over microsatellite panels has been demonstrated in
theory [45] and in practice [46]. Our analysis of 279 families in
Total Category 1 included 129 of the 137 sibships in the previous
study plus an independent cohort of 150 sibships. For a set of 300
sibpairs the power to detect linkage is nearly 100% for an allele
conferring a two-fold increased risk to siblings of affected
individuals [47,48]. If genes with such magnitudes of effect exist
they may be the most relevant to the study of human aging, and
our scan would be well-powered to detect them.
Across ten categories of minimum expected age at death
requirements, we identified three novel loci of interest: an Overall
genomewide significant peak on chromosome 3p24-22
(LOD=4.02, P=0.037), a highly suggestive peak on chromosome
9q31-34 (LOD=3.89, P=0.054), and a peak on chromosome
12q24 (LOD=4.05) in the newly recruited subset of our subjects.
These linkage peaks are preliminary results that warrant
replication studies, as several factors may influence their
significance (Text S6). None of our scans provided substantial
evidence for linkage to FOXO3 on chromosome 6, probably
because of the relatively small effect sizes conferred by SNPs at
that locus [13–18]. Consistent with previous studies [24,49], the
APOE gene on chromosome 19 was likewise not linked in any
analysis, again possibly due to the low relative mortality risks of the
e2 and e4 haplotypes [50]. In addition, the e4 haplotype
predisposes young individuals to elevated mortality rates and is
thus depleted in the exceptionally old [11], but such negatively
selected alleles do not result in significant excess allele sharing
among long-lived siblings [49]. By contrast, the e2 haplotype is
enriched in the exceptionally old [11], but the apparent protective
effect may be mediated by a heterozygote advantage mechanism
[50-52]. The e2 haplotype is then analogous to a rare dominant
variant, for which the power of allele-sharing methods is also low
[49,53].
The only previous genomewide linkage scan for exceptional
longevity used a minimum actual age at death or last contact of 98
for probands and 91 or 95 for additional male or female siblings,
Figure 1. Genomewide nonparametric LOD scores by age category for Total group. Chromosome number is indicated at the bottom of
each plot. Red line denotes empirical genomewide significance threshold across all age categories of LOD=3.9.
doi:10.1371/journal.pone.0012432.g001
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The previous study produced distinct linkage peaks at both the
3p24-22 and 9q31-34 loci reported here, but with relatively small
LOD scores of about 0.8 and 1.0, respectively. Our corresponding
Overall maximum LOD scores for the two peaks in the Previous
subgroup were 4.49 and 3.43 in Categories 5 and 8, but the scores
in Category 1 were only 3.22 and 0.18. The chromosome 12
linkage peak reported here only in the New subgroup was
completely absent from the previous study. Therefore, compared
to the previous scan the discovery of the three novel loci was
probably most attributable to different factors in each case: the
increased informativity of the 10K marker panel for chromosome
3, the use of a range of age cutoffs for chromosome 9, and the
expansion of our sample set for chromosome 12. Other previous
scans using age-related traits have provided some evidence for
linkage to chromosome 3p [25,27], but given the disparate
phenotypes and coarse microsatellite maps in these studies, it is
difficult to assess the relevance of their data to our results.
Future linkage studies may benefit in power from denser marker
panels [54] and larger sample sizes, but detection of loci with small
effects and gene identification require other methods [55]. An
association study of genes under the previously reported
chromosome 4q22-25 linkage peak [24] implicated a SNP in the
promoter of MTTP (MIM 157147) as associated with longevity
[28], but multiple attempts to replicate this result were
unsuccessful [12,26,28,56-58]. It has been suggested that these
studies also cast doubt on the prior linkage evidence [59], when in
fact the two issues are largely independent, and this study was the
first adequately powered attempt to replicate the previous scan.
Although we were unable to reproduce the chromosome 4 linkage
in the Total group or independent New subgroup, the evidence
was stronger when only sibships used in the original study were
analyzed (Overall maximum LOD score of 2.20 in Previous
Category 3), indicating heterogeneity between subgroups. Impor-
tantly, only 129 of the 137 original sibships were available for this
study, which could help account for the failure of our LOD score
in Previous Category 1 (2.14) to reach the LOD score of 3.65
reported previously [24]. However, the Maximum LOD Score
(MLS) statistic [60,61] with the possible triangle constraint [62], as
implemented by GeneHunter [33] in the original report [24], was
later documented to result in a slight anticonservative bias that was
most pronounced in small sample sizes [34]. The Kong and Cox
LOD score [32] used here was not subject to that bias [34],
possibly indicating the LOD score from the previous scan was
somewhat inflated relative to our scan.
Several candidate genes in the linkage peaks discussed here
warrant mention. The gene TOP2B (MIM 126431) in the
chromosome 3 linkage peak encodes an isozyme of topoisomerase
II, which is potently inhibited by resveratrol and related
compounds from grape cell culture [63]. Resveratrol can mimic
the effects of caloric restriction, mitigate the symptoms of age-
related diseases, and/or extend lifespan in a variety of model
organisms, including mammals [64,65]. Various human topo-
isomerase homologs have also been shown to regulate cellular
senescence [66,67], promote telomere stability [68], and interact
Figure 2. Nonparametric LOD scores by group for chromo-
somes 3, 9, 12, and 4 linkage peaks. LOD scores for the entire
chromosome are plotted for the Category that produced the highest
LOD score in the Total group for chromosomes 3 and 9, and the highest
LOD score in the New and Previous subgroups for chromosomes 12 and
4, respectively. A) Chromosome 3, Category 4. B) Chromosome 9,
Category 8. C) Chromosome 12, Category 6. D) Chromosome 4,
Category 3.
doi:10.1371/journal.pone.0012432.g002
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BLM (MIM 604610) [70], in which mutations cause the progeroid
disorders Werner syndrome [71] and Bloom syndrome [72],
respectively. DBC1 (MIM 602865) in the chromosome 9 linkage
peak directly interacts with SIRT1 (MIM 604479) and inhibits its
activity [73]; SIRT1 is activated by resveratrol [74] and has been
implicated in several age-related phenotypes in mammals [75].
The sirtuin family members are key regulators of lifespan in yeast
[76], worms [77], and flies [78] and mediate the effects of caloric
restriction [79,80], the only behavior known to increase lifespan in
a wide variety of organisms, including mammals [81]. In response
to nutrient withdrawal, SIRT1 is stimulated by FOXO3 [82], in
which variants have been reproducibly associated with human
longevity [13–18]. In addition, different SNPs in or near TLR4
(MIM 603030) in the chromosome 9 linkage peak have been
associated at least once, though often not reproducibly, with
exceptional longevity in men [83,84], a bone-related proxy for
biological age [85], and various age-related diseases [86]. Also of
note, mutations in ANK2 (MIM 106410), in the previously
reported chromosome 4 linkage peak, cause long-QT syndrome
[87], and common variation in ANK2 has been reported to
regulate the QT interval [88]. QT interval prolongation is a risk
factor for sudden cardiac death in healthy individuals [89] as well
as those with ischemic heart disease [90] and chronic congestive
heart failure [91], which are more common causes of death
among centenarians than younger individuals [92]. Heterozygous
Ank2
+/2 knockout mice displayed multiple signs of premature
senescence and their lifespan was significantly reduced compared
to wild-type littermates [93]. Finally, a nominally significant
association was reported between a SNP in ALPK1 (MIM 607347)
and both age at death and morbidity-free status at age 65 [85].
Both ANK2 and ALPK1 are within the 99% confidence (-2 LOD)
[94] interval for the original chromosome 4 linkage peak [24] but
are outside the 85%confidence(-1 LOD)interval testedin the study
that identified MTTP [28], raising the possibility that ANK2, ALPK1,
or another gene besides MTTP could explain the previous linkage
result. The positions of all the above genes within linkage peaks
suggest they merit attention in future gene identification efforts.
The linkage scans reported here should contribute to the
analysis of both linkage and association studies on exceptional
Table 2. Characteristics of chromosomes 3, 9, 12, and 4 linkage peaks.
Locus 3p24.2–22.3 9q31.3–34.2 12q24.31–24.33 4q21.21–28.1
Age category reported 4863
Total max LOD (d) 4.02 (0.288) 3.89 (0.498) 1.11 (0.168)
a 1.01 (0.135)
c
Total max hLOD dominant (a) 3.334 (0.329) 3.883 (0.792)
b NA NA
Total max hLOD recessive (a) 4.652 (0.271) 2.680 (0.364)
b NA NA
99% (22 LOD) left confidence boundary rs2362772 rs723706 rs606443 rs726896
Build 37.1 left boundary location 24918232 112778426 120910630 81213792
Peak maximum rs28150 rs536861 rs1732462 rs1008326
Build 37.1 maximum location 29594086 128313444 127444592 110563638
99% (22 LOD) right confidence boundary rs1382554 rs1074052
b rs953182 rs1586149
Build 37.1 right boundary location 35093841 136462498
b 129106410 127074788
Category-specific empirical P value 0.006 0.012 NA NA
Overall empirical P value 0.037 0.054 NA NA
Overall P value upper 95% confidence limit 0.048 0.067 NA NA
Previous max LOD (d) 4.49 (0.464)
a 3.43 (0.636) ,1 2.20 (0.298)
Previous max hLOD dominant (a) 4.029 (0.534)
a 3.187 (0.833) NA 1.954 (0.358)
Previous max hLOD recessive (a) 4.527 (0.389)
a 2.766 (0.410) NA 1.966 (0.241)
New max LOD (d) 1.19 (0.220) 1.12 (0.377) 4.05 (0.504) ,1
New max hLOD dominant (a) NA NA 3.915 (0.605) NA
New max hLOD recessive (a) NA NA 3.875 (0.386) NA
MC max LOD (d) 1.85 (0.260) 3.62 (0.603) ,1 ,1
MC max hLOD dominant (a) NA 3.145 (0.678) NA NA
MC max hLOD recessive (a) NA 3.121 (0.377) NA NA
FO max LOD (d) 2.77 (0.402)
a 1.33 (0.622)
b ,1 ,1
FO max hLOD dominant (a) 2.499 (0.458)
a NA NA NA
FO max hLOD recessive (a) 3.500 (0.357)
a NA NA NA
Overall maximum LOD scores were noted if greater than or equal to 1, and hLOD scores were noted for peaks with LOD scores greater than or equal to 2. The
parameters a and d represent the proportion of families that are linked (parametric analyses), and the magnitude of excess allele-sharing (nonparametric analyses),
respectively. Boundaries are for the Total group for chromosomes 3 and 9, the New subgroup for chromosome 12, and the Previous subgroup for chromosome 4. The
boundaries of the chromosome 9 peak are a composite of Categories 8 and 9, which had overlapping but slightly offset peaks of similar magnitude. NA, not applicable
(scores were not noted or P values were not determined).
aCategory 5.
bCategory 9.
cCategory 2.
doi:10.1371/journal.pone.0012432.t002
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Since cross-sectional study designs for longevity are subject to
unique methodological complications [11] and longitudinal cohort
designs can be prohibitively expensive, case-control studies will
benefit from direction or corroboration by linkage scans. For
example, the extensive multiple testing problem encountered in
genomewide association studies can be partially alleviated by a
weighted Bonferroni correction or Bayesian analysis that employs
linkage data [96]. Alternatively, our results could help inform deep
resequencing efforts to identify rare variants that influence
lifespan, a particularly suitable approach for genes in which
multiple variants exert individual effects too weak to be detected
by association methods. Discovery and confirmation of human
longevity genes will provide insight into the biology of aging and
the genetic basis for resistance to age-related disease.
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